Sanofi

CAC 40Health careSANFR0000120578

A. is a French multinational pharmaceutical and healthcare company headquartered in Paris.

Filings

431 filings

All Inside information267 Share buyback113 Voting rights and capital36 Earnings release9 Half-year financial report2 Universal registration document2 Threshold crossing1 Annual financial report1

30/03/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
28/03/2026
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Inside informationFR
27/03/2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
Inside informationFR
24/03/2026
Press release: Availability of the Q1 2026 aide-mémoire
Inside informationFR
24/03/2026
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Inside informationFR
23/03/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
18/03/2026
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Inside informationFR
16/03/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
12/03/2026
Sanofi: Information concerning the total number of voting rights and shares - February 2026
Voting rights and capitalFR
09/03/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
05/03/2026
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
Inside informationFR
04/03/2026
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
Inside informationFR
02/03/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
02/03/2026
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Inside informationFR
27/02/2026
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Inside informationFR
24/02/2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Inside informationFR
23/02/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
17/02/2026
Annual report 2025 Form 20-F
Annual financial reportZIP
17/02/2026
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Inside informationFR
17/02/2026
Document d'enregistrement universel 2025
Universal registration documentFrenchZIP
17/02/2026
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Inside informationFR
16/02/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
16/02/2026
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
Inside informationFR
12/02/2026
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
Inside informationFR
11/02/2026
Sanofi: Information concerning the total number of voting rights and shares – January 2026
Voting rights and capitalFR
10/02/2026
Press Release: Sanofi completes the acquisition of Dynavax
Inside informationFR
09/02/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
03/02/2026
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
Inside informationFR
30/01/2026
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Inside informationFR
29/01/2026
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
Inside informationFR
23/01/2026
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
Inside informationFR
15/01/2026
Press Release: Myqorzo and Redemplo approved in China
Inside informationFR
14/01/2026
Sanofi: Information concerning the total number of voting rights and shares - December 2025
Voting rights and capitalFR
12/01/2026
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Inside informationFR
05/01/2026
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Inside informationFR
02/01/2026
Sanofi: Disclosure of trading in own shares
Share buybackFR
29/12/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
24/12/2025
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Inside informationFR
24/12/2025
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Inside informationFR
23/12/2025
Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
Inside informationFR
23/12/2025
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Inside informationFR

About

ISIN: FR0000120578
Ticker: SAN
LEI: 549300E9PC51EN656011
Sector: Health care
Founded: 2004
Employees: 106,566
Country of registration: FR
Last filing: 04/08/2026, 07:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive